FINWIRES · TerminalLIVE
FINWIRES

Aurobindo Pharma Gets US FDA's Final Nod for Glycerol Phenylbutyrate Oral Liquid

-- Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) has received final approval from the US Food and Drug Administration (US FDA) to manufacture and market Glycerol Phenylbutyrate Oral Liquid, according to a Friday filing to the Indian stock exchanges.

The drug is bioequivalent and therapeutically equivalent to Horizon Therapeutics' reference-listed drug Ravicti Oral Liquid. It will be manufactured in the company's third unit and will be launched immediately.

Glycerol Phenylbutyrate is used as a nitrogen-binding agent for chronic management of patients with urea cycle disorders.

According to IQVIA's estimates, Horizon has an estimated market size of $50.2 million for the 12 months ended February.

Related Articles

Asia

Beijing Enlight Media Q1 Profit Falls 99%; Shares Down 8%

Beijing Enlight Media Co (SHE:300251) posted first-quarter attributable net profit of 23.3 million yuan, down 99% from 2.02 billion yuan the previous year.Earnings per share went down to 0.01 yuan from 0.69 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue fell 94% year over year to 190.6 million yuan from 2.97 billion yuan.Shares of the media company were down 8% in recent trade.

$SHE:300251
Asia

Enlight Media 2025 Profit Jumps 473%; Shares Fall 7%

Beijing Enlight Media (SHE:300251) posted 2025 attributable net profit of 1.67 billion yuan, up 473% from 292.0 million yuan the previous year.Earnings per share went up to 0.57 yuan from 0.10 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue jumped 155% year over year to 4.04 billion yuan from 1.59 billion yuan.Shares of the media company were down 7% in recent trade.

$SHE:300251
Asia

CR Double-Crane Pharma Gets Nod to Name Unit as Marketer of Endometriosis Drug

China Resources Double-Crane Pharmaceutical (SHA:600062) received approval from the National Medical Products Administration to change the marketing authorization holder of dienogest tablets, according to a Shanghai bourse filing on Wednesday.Under the approved supplementary application, the pharmaceutical company's subsidiary, CR Zizhu Pharmaceutical, becomes the marketing authorization holder, as well as the manufacturer of the endometriosis drug.

$SHA:600062